Press release: VMD grants marketing authorisation for Syvazul® BTV3 in United Kingdom

Syvazul® BTV 3 has been granted a marketing authorisation in United Kingdom for use in cattle and sheep, with a reduced dose in cattle.

León, 4 July 2025 – Syva is pleased to announce that Syvazul® BTV 3 has been granted a marketing authorisation (Vm 31592/5006) in UK, allowing its use in cattle and sheep to combat Bluetongue virus serotype 3 (BTV-3). The authorisation, effective from 3 July 2025, is valid indefinitely.

A major update for cattle: reduced dose
A key breakthrough in this new authorisation is that the dose for cattle has been reduced from 4 ml to 2 ml, improving convenience and aligning with the latest regulatory data. Reminder Indications and administration

Cattle

• For active immunisation to reduce viraemia caused by BTV-3.
• Onset of immunity: 3 weeks after completing the primary vaccination course.

Dosage (intramuscular):

• From 2 months of age in naïve animals, or from 3 months if born to immune dams.
• Primary vaccination: 2 doses of 2 ml, 3 weeks apart.

Sheep

• For active immunisation to reduce viraemia, mortality, clinical signs and lesions caused by BTV-3.
• Onset of immunity: 4 weeks after completing the primary vaccination course.

Dosage (subcutaneous):

• From 3 months of age.
• Primary vaccination: 1 single dose of 2 ml.